Moreno S - Search Results

1

Risk of clinically significant depression in HIV-infected patients: effect of antiretroviral drugs.

Gutiérrez F, García L, Padilla S, Alvarez D, Moreno S, Navarro G, Gómez-Sirvent J, Vidal F, Asensi V, Masiá M; CoRIS. Gutiérrez F, et al. Among authors: moreno s. HIV Med. 2014 Apr;15(4):213-23. doi: 10.1111/hiv.12104. Epub 2013 Nov 11. HIV Med. 2014. PMID: 24215356 Free article.

2

Group A streptococcal bacteremia. A 10-year prospective study.

Bernaldo de Quirós JC, Moreno S, Cercenado E, Diaz D, Berenguer J, Miralles P, Catalán P, Bouza E. Bernaldo de Quirós JC, et al. Among authors: moreno s. Medicine (Baltimore). 1997 Jul;76(4):238-48. doi: 10.1097/00005792-199707000-00002. Medicine (Baltimore). 1997. PMID: 9279330 Free article. Review.

3

Effectiveness and pitfalls of initial highly active antiretroviral therapy in HIV-infected patients in routine clinical practice.

Moreno A, Perez-Elías MJ, Casado JL, Muñoz V, Antela A, Dronda F, Navas E, Fortún J, Quereda C, Moreno S. Moreno A, et al. Among authors: moreno s. Antivir Ther. 2000 Dec;5(4):243-8. Antivir Ther. 2000. PMID: 11142618 Clinical Trial.

4

Visceral leishmaniasis in human immunodeficiency virus (HIV)-infected and non-HIV-infected patients. A comparative study.

Pintado V, Martín-Rabadán P, Rivera ML, Moreno S, Bouza E. Pintado V, et al. Among authors: moreno s. Medicine (Baltimore). 2001 Jan;80(1):54-73. doi: 10.1097/00005792-200101000-00006. Medicine (Baltimore). 2001. PMID: 11204503 Free article.

5

A clinical study of the combination of 100 mg ritonavir plus 800 mg indinavir as salvage therapy: influence of increased plasma drug levels in the rate of response.

Casado JL, Moreno A, Sabido R, Martí-Belda P, Antela A, Dronda F, Perez-Elías MJ, Moreno S. Casado JL, et al. Among authors: moreno s, moreno a. HIV Clin Trials. 2000 Jul-Aug;1(1):13-9. doi: 10.1310/gmw7-h051-7wh5-2cxh. HIV Clin Trials. 2000. PMID: 11590485 Clinical Trial.

6

Consensus conference on chronic viral hepatitis and HIV infection: updated Spanish recommendations.

Soriano V, Miró JM, García-Samaniego J, Torre-Cisneros J, Núñez M, del Romero J, Martín-Carbonero L, Castilla J, Iribarren JA, Quereda C, Santín M, González J, Arribas JR, Santos I, Hernández-Quero J, Ortega E, Asensi V, del Pozo MA, Berenguer J, Tural C, Clotet B, Leal M, Mallolas J, Sánchez-Tapias JM, Moreno S, Gatell JM, Téllez MJ, Rubio R, Ledesma E, Domingo P, Barreiro P, Pedreira J, Romero M, González-Lahoz J, Lissen E. Soriano V, et al. Among authors: moreno s. J Viral Hepat. 2004 Jan;11(1):2-17. doi: 10.1046/j.1365-2893.2003.00491.x. J Viral Hepat. 2004. PMID: 14738553 Review.

7

Limitations of a simplification antiretroviral strategy for HIV-infected patients with decreasing adherence to a protease inhibitor regimen.

Moya J, Casado JL, Aranzabal L, Moreno A, Antela A, Dronda F, Perez-Elías MJ, Marin A, Moreno S. Moya J, et al. Among authors: moreno s, moreno a. HIV Clin Trials. 2006 Jul-Aug;7(4):210-4. doi: 10.1310/hct0704-210. HIV Clin Trials. 2006. PMID: 17065033 Clinical Trial.

8

Effect of food on the antiviral activity of didanosine enteric-coated capsules: a pilot comparative study.

Hernández-Novoa B, Antela A, Gutiérrez C, Pérez-Molina JA, Pérez-Elías MJ, Dronda F, Moreno A, Casado JL, Page C, Pumares M, Galán JC, Moreno S. Hernández-Novoa B, et al. Among authors: moreno s, moreno a. HIV Med. 2008 Apr;9(4):187-91. doi: 10.1111/j.1468-1293.2008.00543.x. Epub 2008 Feb 21. HIV Med. 2008. PMID: 18298579 Free article. Clinical Trial.

9

Immunization with an HIV-1 immunogen induces CD4+ and CD8+ HIV-1-specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapy.

Valor L, Navarro J, Carbone J, Rodríguez-Sáinz C, Gil J, López F, Fernández-Cruz E; STIR-2102 Team. Valor L, et al. Vaccine. 2008 May 23;26(22):2738-45. doi: 10.1016/j.vaccine.2008.03.019. Epub 2008 Apr 1. Vaccine. 2008. PMID: 18433946 Clinical Trial.

10

Didanosine, lamivudine, and efavirenz versus zidovudine, lamivudine, and efavirenz for the initial treatment of HIV type 1 infection: final analysis (48 weeks) of a prospective, randomized, noninferiority clinical trial, GESIDA 3903.

Berenguer J, González J, Ribera E, Domingo P, Santos J, Miralles P, Angels Ribas M, Asensi V, Gimeno JL, Pérez-Molina JA, Terrón JA, Santamaría JM, Pedrol E; GESIDA 3903 Team. Berenguer J, et al. Clin Infect Dis. 2008 Oct 15;47(8):1083-92. doi: 10.1086/592114. Clin Infect Dis. 2008. PMID: 18781872 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

2,044 results

Search Page

Filters